IMI plans change in name to PreMD Inc.

IMI plans change in name to PreMD Inc.
New name reflects evolution of company from development-stage biotech to
innovator in predictive medicine 


TORONTO, May 25  /PRNewswire-FirstCall/ -- IMI International Medical
Innovations Inc.   (TSX: IMI; Amex: IME) plans to change its name to PreMD Inc.
later this year to better reflect the company's predictive medicine focus and
growth direction, announced Dr. Brent Norton, President and Chief Executive
Officer, at the company's annual shareholders' meeting today in Toronto. The
new name will be officially launched in September 2005.

"This important strategic step acknowledges just how far we have come since our
inception," said Dr. Norton. "We have evolved from a development- stage company
to one with a world-class marketing partnership with McNeil Consumer
Healthcare. From a mere concept we have developed a predictive heart disease
test, PREVU(x) Point of Care Skin (POC) Sterol Test, that is now being
commercialized. We have a very promising pipeline of non-invasive cancer
detection tests with equal potential to be marketable products. And, underlying
all of this, we have established significant scientific credibility and earned
the respect of the international medical community."

The name PreMD Inc. describes the role the company's products fulfill:
predicting disease at an early stage in order to prevent its progression, or
from occurring at all. "Pre" means "before a time or event". MD, the acronym
for "medical doctor", when combined with "Pre" suggests the early management
and monitoring of one's health. PreMD reflects the company's focus on
empowering patients and doctors alike to better manage total health and
wellness.

Dr. Norton continued, "Our new name sets the tone for an equally exciting
future as we strive to capitalize on myriad growth opportunities. PreMD helps
to communicate our company's leading position in the predictive medicine field
and provides a strong corporate brand platform upon which to build awareness
and shareholder value."

The effective date of the corporate name change to PreMD Inc. will be announced
in September 2005. The new corporate website will be http://www.premdinc.com/
and the company's shares are currently expected to trade on the Toronto Stock
Exchange under the symbol PMD and on the American Stock Exchange under the
symbol PME.

About IMI

IMI (http://www.imimedical.com/) is a world leader in predictive medicine,
dedicated to developing rapid, non-invasive tests for the early detection of
life-threatening diseases. IMI's cardiovascular products, branded as PREVU(x)
Skin Sterol Test, are marketed and distributed worldwide by McNeil Consumer
Healthcare. The company's cancer tests include ColorectAlert(TM), LungAlert(TM)
and a breast cancer test. IMI's head office is located in Toronto, and its
research and product development facility is at McMaster University in
Hamilton, Ontario.

This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward-
looking statements. Such risks and uncertainties include, among others, the
successful development or marketing of the Company's products, the
competitiveness of the Company's products if successfully commercialized, the
lack of operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, product
liability, reliance on third-party manufacturers, the ability of the Company to
take advantage of business opportunities, uncertainties related to the
regulatory process, the inability of the Company to change its name to PreMD
Inc. in the time projected due to any reason, and general changes in economic
conditions.

In addition, while the Company routinely obtains patents for its products and
technology, the protection offered by the Company's patents and patent
applications may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain patent
protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks
and uncertainties relating to the forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. IMI is providing
this information as of the date of this press release and does not undertake
any obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise. 

DATASOURCE: IMI International Medical Innovations Inc.



CONTACT: For more information, please contact: Company Contact: Sarah

Borg-Olivier, Director, Communications, T: [phone],

; U.S. Investor Contact: Andrea Faville, John

Nesbett, The Investor Relations Group, T: [phone],

,

Copyright